Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GRK2 | P25098 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL9935681 | 0.87 | SLC22A1 (0.46) | BBOX1TSHRALDH1A1DNM1SLC22A1 | |
| SCHEMBL9935787 | 0.84 | SLC22A1 (0.38) | BBOX1MEN1LMNAPOLBGRK2 | |
| SCHEMBL9934679 | 0.84 | DNM1 (0.42) | BBOX1MEN1LMNAPOLBGRK2 | |
| SCHEMBL9935909 | 0.84 | SLC22A1 (0.38) | BBOX1MEN1LMNAPOLBGRK2 | |
| Tributylmethylammonium SCHEMBL9935351 | 0.82 | BBOX1 (0.42) | BBOX1MEN1LMNAPOLBGRK2 | |
| SCHEMBL9934336 | 0.82 | DNM1 (0.52) | BBOX1MEN1LMNAKMT2ATSHR | |
| SCHEMBL9935055 | 0.82 | DNM1 (0.52) | BBOX1MEN1LMNAKMT2ATSHR | |
| Tributylmethylammonium SCHEMBL9936102 | 0.81 | ENPP2 (0.33) | TSHRALDH1A1DNM1SLC22A1 | |
| SCHEMBL9935873 | 0.80 | BBOX1 (0.36) | BBOX1 | |
| Tributylmethylammonium SCHEMBL9936137 | 0.80 | MEN1 (0.36) | BBOX1MEN1LMNAPOLBGRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546609-B2 | Ionic liquid containing allylsulfonate anion | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| EP-2474527-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | Wako Pure Chemical Industries, Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157680-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157680-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | ATXN2L, ARL1, INPPL1 | BBOX1 4837/4885MEN1 4362/4885LMNA 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.